ICB therapeutics targeting programmed cell death 1/ligand 1 (PD-1/PD-L1) and cytotoxic T lymphocyte associated protein 4 (CTLA-4) have shown efficacy in a variety of T cell–inflamed cancers [8]. Here, PDCD1 is linked to cancer.